1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy - Drugs In Development, 2022, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching and muscle weakness. Causes include traumas or injuries, genetic, liver disease, hypoxic condition, Lyme disease and organ failure.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Encephalopathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Encephalopathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Encephalopathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Encephalopathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalopathy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Encephalopathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Encephalopathy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Encephalopathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Encephalopathy (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Encephalopathy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Encephalopathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Encephalopathy - Overview
- Encephalopathy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Encephalopathy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Encephalopathy - Companies Involved in Therapeutics Development
- ANLBio Co Ltd
- Argenica Therapeutics Ltd
- Biom Therapeutics LLC
- BrainRepair UG
- F. Hoffmann-La Roche Ltd
- Gene Therapy Research Institution Co Ltd
- Hope Biosciences LLC
- Jazz Pharmaceuticals Plc
- JS Genetics Inc
- Mesoblast Ltd
- Mithra Pharmaceuticals SA
- Mononuclear Therapeutics Ltd
- Orphan Star Therapeutics LLC
- Pfizer Inc
- Pharmazz Inc
- ProThera Biologics Inc
- ReAlta Life Sciences Inc
- Rohto Pharmaceutical Co Ltd
- SL Bigen Co Ltd
- Worphmed Srl
- Encephalopathy - Drug Profiles
- Alda-1 - Drug Profile
- Product Description
- Mechanism Of Action
- ANL-302 - Drug Profile
- Product Description
- Mechanism Of Action
- ARG-007 - Drug Profile
- Product Description
- Mechanism Of Action
- BIO-018 - Drug Profile
- Product Description
- Mechanism Of Action
- BM-1021 - Drug Profile
- Product Description
- Mechanism Of Action
- cannabidiol - Drug Profile
- Product Description
- Mechanism Of Action
- Cell Therapy for Autoimmune Disorders, Cardiovascular Disorders, CNS Disorders, Infectious Disease, Musculoskeletal Disorders and Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- CL-2020 - Drug Profile
- Product Description
- Mechanism Of Action
- diazoxide - Drug Profile
- Product Description
- Mechanism Of Action
- Drugs to Target SLC2A1 for Glut1 Deficiency Syndrome - Drug Profile
- Product Description
- Mechanism Of Action
- estetrol - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Activate SLC2A1 for GLUT1 Deficiency Syndrome - Drug Profile
- Product Description
- Mechanism Of Action
- GT-0006X - Drug Profile
- Product Description
- Mechanism Of Action
- MCC-950 - Drug Profile
- Product Description
- Mechanism Of Action
- melatonin - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibody to Inhibit IL-2 for Encephalopathy, Graft Versus Host Disease and Type 1 Diabetes - Drug Profile
- Product Description
- Mechanism Of Action
- Proteins for Hypoxic-Ischemic Brain Injury - Drug Profile
- Product Description
- Mechanism Of Action
- remestemcel-L - Drug Profile
- Product Description
- Mechanism Of Action
- RLS-0071 - Drug Profile
- Product Description
- Mechanism Of Action
- sovateltide - Drug Profile
- Product Description
- Mechanism Of Action
- Stem Cell Therapy for Anemia and Hypoxic Ischemic Encephalopathy - Drug Profile
- Product Description
- Mechanism Of Action
- Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia - Drug Profile
- Product Description
- Mechanism Of Action
- THDG-3 - Drug Profile
- Product Description
- Mechanism Of Action
- UDI-001 - Drug Profile
- Product Description
- Mechanism Of Action
- Encephalopathy - Dormant Projects
- Encephalopathy - Discontinued Products
- Encephalopathy - Product Development Milestones
- Featured News & Press Releases
- Oct 04, 2022: Argenica receives $1.38m R&D Tax Incentive cash refund for FY22
- Sep 29, 2022: Further positive preclinical results for arg-007 in hypoxic-ischaemic encephalopathy
- Aug 29, 2022: Pharmazz announces Indian Central Drugs Standard Control Organization (CDSCO) Clearance of IND to conduct a Phase II clinical trial of sovateltide (PMZ-1620) in hypoxic-ischemic encephalopathy in neonates
- Jun 23, 2022: USA FDA grants Fast Track Designation to ReAlta Life Sciences’ lead compound RLS-0071 for the treatment of Hypoxic-Ischemic Encephalopathy in neonates
- Jun 02, 2022: ReAlta doses first subjects in Phase Ib severe asthma therapy trial
- May 10, 2022: Germany’s BfArM approves ReAlta Life Science’s phase 1b inhaled LPS challenge trial to support development of RLS-0071 in severe asthma
- Apr 27, 2022: ReAlta Life Sciences partners with Hope for HIE to improve neonatal brain injury outcomes and quality of life
- Apr 04, 2022: ReAlta Life Sciences’ RLS-0071 demonstrates excellent safety profile and confirmed target engagement in first-in-human phase 1 clinical trial
- Mar 31, 2022: ReAlta gets FDA clearance for Phase II HIE therapy trial in neonates
- Mar 04, 2022: ReAlta Life Sciences announces poster presentation at the American Academy of Neurology 2022 Annual Meeting
- Feb 03, 2022: Pharmazz submits Investigational New Drug Application to India Central Drugs Standard Control Organization for a phase II clinical trial of sovateltide (PMZ-1620) in hypoxic-ischemic encephalopathy in neonates
- Dec 09, 2021: Argenica to be granted patent protection in the United States, one of the world’s largest healthcare markets
- Nov 16, 2021: MPO data presented at ACR 2021
- Nov 03, 2021: Argenica Therapeutics: Positive preclinical data for ARG-007 neuroprotection in hypoxicischaemic encephalopathy
- May 18, 2021: ReAlta Life Sciences expands phase 1 clinical trial of RLS-0071 to include three multiple-ascending dose cohorts and an additional single ascending dose cohort
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Encephalopathy, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Encephalopathy - Pipeline by ANLBio Co Ltd, 2022
- Encephalopathy - Pipeline by Argenica Therapeutics Ltd, 2022
- Encephalopathy - Pipeline by Biom Therapeutics LLC, 2022
- Encephalopathy - Pipeline by BrainRepair UG, 2022
- Encephalopathy - Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Encephalopathy - Pipeline by Gene Therapy Research Institution Co Ltd, 2022
- Encephalopathy - Pipeline by Hope Biosciences LLC, 2022
- Encephalopathy - Pipeline by Jazz Pharmaceuticals Plc, 2022
- Encephalopathy - Pipeline by JS Genetics Inc, 2022
- Encephalopathy - Pipeline by Mesoblast Ltd, 2022
- Encephalopathy - Pipeline by Mithra Pharmaceuticals SA, 2022
- Encephalopathy - Pipeline by Mononuclear Therapeutics Ltd, 2022
- Encephalopathy - Pipeline by Orphan Star Therapeutics LLC, 2022
- Encephalopathy - Pipeline by Pfizer Inc, 2022
- Encephalopathy - Pipeline by Pharmazz Inc, 2022
- Encephalopathy - Pipeline by ProThera Biologics Inc, 2022
- Encephalopathy - Pipeline by ReAlta Life Sciences Inc, 2022
- Encephalopathy - Pipeline by Rohto Pharmaceutical Co Ltd, 2022
- Encephalopathy - Pipeline by SL Bigen Co Ltd, 2022
- Encephalopathy - Pipeline by Worphmed Srl, 2022
- Encephalopathy - Dormant Projects, 2022
- Encephalopathy - Discontinued Products, 2022
- Number of Products under Development for Encephalopathy, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ANLBio Co Ltd
- Argenica Therapeutics Ltd
- Biom Therapeutics LLC
- BrainRepair UG
- F. Hoffmann-La Roche Ltd
- Gene Therapy Research Institution Co Ltd
- Hope Biosciences LLC
- Jazz Pharmaceuticals Plc
- JS Genetics Inc
- Mesoblast Ltd
- Mithra Pharmaceuticals SA
- Mononuclear Therapeutics Ltd
- Orphan Star Therapeutics LLC
- Pfizer Inc
- Pharmazz Inc
- ProThera Biologics Inc
- ReAlta Life Sciences Inc
- Rohto Pharmaceutical Co Ltd
- SL Bigen Co Ltd
- Worphmed Srl
